Medical and Neurological Complications After TBI
TBI · EP 07 · NEUROTRAUMA
Before You Listen
- Prerequisites: Glasgow Coma Scale (GCS) severity stratification; basic ventricular and cisternal cerebrospinal fluid (CSF) anatomy; the difference between upper motor neuron (UMN) and lower motor neuron (LMN) signs; Modified Ashworth Scale (MAS) for spasticity.
- Runtime: 1 hour 4 minutes.
- Topic in one line: post-traumatic seizures (PTS) and the Temkin 7-day rule, post-traumatic hydrocephalus and the Hakim-Adams triad, the cranial nerve (CN) 1-7-8 ranking, convergence insufficiency at the 5 cm vestibular ocular motor screening (VOMS) threshold, heterotopic ossification (HO) at the hip with alkaline phosphatase as the earliest marker, venous thromboembolism (VTE) prophylaxis sequencing, paroxysmal sympathetic hyperactivity (PSH), post-traumatic headache, sleep architecture failure, post-traumatic hypopituitarism with the Ghigo screening algorithm, neurogenic bladder/bowel patterns specific to TBI, and pressure injury staging on the Braden Scale.
Vignette. A 58-year-old man is 8 weeks out from a severe TBI sustained in a fall from a roof. During inpatient rehabilitation, the nursing team reports that his right hip will not flex past 70 degrees during morning stretches, and the periarticular tissue feels warm and firm. A serum alkaline phosphatase drawn that morning is 312 U/L (baseline 95). Plain radiographs of the hip are unremarkable. He has been on enoxaparin since hospital day 3 and his last venous duplex was negative one week ago.
What is the most likely diagnosis, the single most sensitive imaging study to confirm it, the prevention strategy that should already have been in place, and the criteria that govern the timing of definitive surgical excision?
Section 1: Post-Traumatic Seizures and the Seven-Day Rule
Bottom line: post-traumatic seizures (PTS) split into immediate (<24 h), early (24 h–7 d), and late (>7 d) categories with different mechanisms; antiepileptic prophylaxis works for the first 7 days only and does nothing for late epilepsy; penetrating injury is the highest-risk profile at 33–50%.
Post-traumatic seizures are seizures that occur as a direct consequence of traumatic brain injury (TBI), and the temporal classification is not arbitrary. Each window reflects a distinct pathophysiology that drives a distinct treatment. Immediate seizures occur within 24 hours of impact and represent direct mechanical depolarization, ionic flux, and glutamate excitotoxicity. They are generally benign impact phenomena and do not predict long-term epilepsy. Early seizures occur between 24 hours and 7 days and result from acute cascades, including cerebral edema, intracranial hemorrhage expansion, blood-brain barrier disruption, and inflammatory mediator release. They drive intracranial pressure and metabolic demand, both of which compound secondary brain injury. Late seizures occur after 7 days and result from chronic processes, including cortical reorganization, gliotic scarring, aberrant network formation through epileptogenesis, iron deposition from hemoglobin degradation, and chronic neuroinflammation. When late seizures recur, the diagnosis becomes post-traumatic epilepsy (PTE).
The 7-day boundary marks the point at which acute provoked seizures (suppressible by drugs) give way to structural epileptogenesis (which current pharmacology cannot stop). Prophylaxis works for the acute window and only for the acute window.
Incidence scales sharply with severity. Mild TBI carries a 1–1.5% overall seizure incidence with <1% late risk. Moderate TBI runs ~2.9%. Severe blunt TBI rises to 12–17% overall with 10–17% late risk. Penetrating TBI sits at 33–50%, the highest of any category, and the risk persists for decades. Combat-related penetrating TBI in military cohorts shows late seizures in roughly 26% of veterans at 7.5-year median follow-up, with elevated risk extending 15–35 years after injury.
Risk factors for late PTS include penetrating injury (33–50%), intracranial hematoma whether epidural, subdural, or intraparenchymal (25–30%, driven by iron from hemoglobin breakdown), early seizure within the first week (~25%), depressed skull fracture (3–70% depending on depth and dural penetration), prolonged coma or post-traumatic amnesia >24 hours (up to 35%), and cortical contusion of temporal or frontal cortex. GCS <10, age >65, craniotomy, and multiple hemorrhage types each independently raise risk.
The evidence base rests on the Temkin trial, a randomized double-blind placebo-controlled study published in the New England Journal of Medicine in 1990 that enrolled 404 patients with serious head trauma. Patients received intravenous phenytoin loading within 24 hours of injury, followed by oral maintenance. Within the first 7 days, the phenytoin arm had a 3.6% early seizure incidence compared to 14.2% with placebo, a ~73% relative risk reduction. Beyond 7 days, late seizures occurred in 21.5% on phenytoin versus 15.7% on placebo, with no statistically significant difference and a numerical trend favoring placebo at 2 years. The Brain Trauma Foundation (BTF) codified this as a Level 2A recommendation: phenytoin (or equivalent) for 7 days, then stop.
Levetiracetam has largely displaced phenytoin in practice. The Inaba 2013 prospective multicenter trial across 9 Level-1 trauma centers (n=813) showed early seizure incidence of 1.5% in both groups, establishing non-inferiority. Levetiracetam is renally cleared (no cytochrome P450 entanglements), needs no drug-level monitoring, and produces less cognitive impairment. Its main caveat is behavioral irritability (“Keppra rage”), which is a real liability in a population already prone to agitation. About 98% of US Level-1 trauma centers now use levetiracetam, although BTF technically still lists phenytoin in the Level 2A recommendation because that was the molecule used in Temkin.
For patients who develop documented PTE requiring chronic anticonvulsant therapy, the generally accepted minimum for considering medication withdrawal is 2 years seizure-free with EEG normalization, with a gradual taper over 2–6 months.
High Yield — Post-traumatic seizures
- Temkin 7-day rule: prophylaxis prevents early (24 h–7 d) seizures, not late epilepsy. Stop at day 7 unless the patient has documented PTE.
- Penetrating TBI = 33–50% late seizure risk, the highest category. Risk persists 15–35 years.
- Levetiracetam has practically replaced phenytoin: no CYP interactions, no level monitoring, less cognitive load. Watch for behavioral irritability.
- Iron from hemoglobin breakdown is directly epileptogenic, which explains the 25–30% late risk after intracranial hematoma.
- Late seizure threshold for PTE diagnosis: ≥1 unprovoked seizure beyond 7 days post-injury (recurrent late seizures = PTE).
Board Trap — Continuing prophylaxis past day 7
The reflex to “keep them on it just in case” is wrong. Continuing phenytoin or levetiracetam beyond 7 days adds cognitive impairment, drug interactions, and gingival hyperplasia (phenytoin) or irritability (levetiracetam) without preventing late epilepsy. Day 8 is when the AED comes off, unless a documented seizure has converted the patient to PTE.
As the spilled blood from the initial injury breaks down, the hemoglobin releases iron, and that iron deposits directly into the brain tissue. Iron is not supposed to be sitting freely in the neural tissue — it is incredibly irritating and highly epileptogenic. The brain’s electrical networks are essentially rewiring themselves in an aberrant, pathological way.
— TBI-07 podcast, ~05:01